Literature DB >> 21837788

Mutations in two PKR-binding domains in chronic hepatitis C of genotype 3a and correlation with viral loads and interferon responsiveness.

Shouichi Yokozaki1, Yoshiaki Katano, Kazuhiko Hayashi, Masatoshi Ishigami, Akihiro Itoh, Yoshiki Hirooka, Isao Nakano, Hidemi Goto.   

Abstract

Interferon (IFN) induces the double-stranded RNA-dependent protein kinase (PKR) to inhibit viral replication. Two motifs of the PKR-binding domain exist in the E2 and the NS5A regions of the hepatitis C virus (HCV). These regions are called the PKR-eukaryotic transcription factor (elF2-alpha) phosphorylation homology domain (PePHD), and the IFN sensitivity-determining region (ISDR). Both regions are inhibited by PKR. Thus, several studies have reported the relationship between these regions and IFN responsiveness and the HCV viral load. However, the data obtained from these studies remain controversial. The aim of this study was to investigate the genomic heterogeneity of the PePHD and the ISDR in patients with genotype 3a and how this impacts HCV replication and the response to IFN therapy. Twenty-one male patients infected with HCV genotype 3a were studied. The PePHD was well conserved, and mutations were found in only one amino acid position in two patients. Patients with three or more mutations in the ISDR had lower viral loads than those with fewer than two mutations (192.2 ± 176.7 vs. 1279.4 ± 997.6 KIU/ml, P = 0.0277). Ten (71.4%) of 14 patients achieved a sustained virological response to IFN therapy. No specific amino acid substitutions in the PePHD and the ISDR were associated with IFN responsiveness; however, the number of mutations in the ISDR was significantly associated with the HCV viral load. The findings from this study suggest that the ISDR plays an important role in regulating viral replication in patients infected with HCV genotype 3a.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21837788     DOI: 10.1002/jmv.21959

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  3 in total

1.  The Relationship Between HCV-NS5A Gene Mutations and Resistance to Combination Therapy in Patients with HCV- Genotype 1-B.

Authors:  Hamed Esmaeil Lashgarian; Ali Valibeik; Abdolrazagh Marzban; Maryam Karkhane; Kiana Shahzamani
Journal:  Rep Biochem Mol Biol       Date:  2021-07

2.  Evolution of viral RNA in a Chinese patient to interferon/ribavirin therapy for hepatitis C.

Authors:  Xian-Zi Wen; Zhi-Hai Chen; Ya-Zhi Wei; Jia-Fu Ji
Journal:  Chin J Cancer Res       Date:  2012-12       Impact factor: 5.087

3.  Study of PKRBD in HCV genotype 3a infected patients in response to interferon therapy in Pakistani population.

Authors:  Atika Mansoor; Lubna Ali; Noor-ul Sabah; Asraf Hussain Hashmi; Mohammad Haroon Khan; Syed Ali Raza Kazmi; Nafees Ahmad; Saima Siddiqi; Khalid Mehmood Khan
Journal:  Virol J       Date:  2013-12-09       Impact factor: 4.099

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.